U.S. drug industry hopes China deal ends stealth attack on IP
Innovators hope trade deal stops China's stealth war on IP
Innovator pharmaceutical manufacturers hope the new “phase one” U.S.-China trade deal will create a cease-fire in the stealth war on pharma IP in China.
The deal, announced Dec. 13, comes at the end of a year when Chinese IP practices have cut short patent exclusivity for at least five innovative drugs.
Details of the agreement may not be released for weeks, but a summary released by the U.S. Trade Representative and leaks to lobbyists suggest that it could include patent linkage policies that would prevent generic launches prior to expiration or invalidation of innovators’ patents.
This would be welcome news to multinational pharmaceutical companies.
The absence of linkage would indicate that more innovative drugs may be at risk in China.